EGFR and non-small cell lung carcinoma: Notably, patients with common EGFR mutations had the highest OS, while those with rare mutations had a shorter survival period, albeit not statistically significant.<h4>Conclusion</h4>This study highlights the relevance of EGFR mutation status in NSCLC patients, particularly in therapeutic decision-making.